Vertex Pharmaceuticals Incorporated (VRTX)의 가격은 얼마입니까?

Vertex Pharmaceuticals Incorporated (VRTX)의 가격은 $454.00입니다.

Vertex Pharmaceuticals Incorporated (VRTX)의 시가 총액은 무엇입니까?

Vertex Pharmaceuticals Incorporated (VRTX)의 시가 총액은 $115.32B입니다.

Vertex Pharmaceuticals Incorporated (VRTX) 발행주식수

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

연도	발행 주식 수	변화
2026 (TTM)	253.90M	-0.70%
2025	255.70M	-0.70%
2024	257.50M	-0.08%
2023	257.70M	0.62%
2022	256.10M	-0.62%
2021	257.70M	-0.82%
2020	259.84M	1.21%
2019	256.73M	0.96%
2018	254.29M	2.18%
2017	248.86M	2.16%
2016	243.59M	1.14%
2015	240.84M	2.52%
2014	234.92M	4.49%
2013	224.83M	6.08%
2012	211.95M	3.44%
2011	204.89M	2.24%
2010	200.40M	15.67%
2009	173.26M	23.27%
2008	140.56M	8.97%
2007	128.99M	13.92%
2006	113.22M	26.87%
2005	89.24M	13.58%
2004	78.57M	2.03%
2003	77.00M	1.66%
2002	75.75M	1.73%
2001	74.46M	10.02%
2000	67.68M	0.00%

연도

발행 주식 수

변화

2026 (TTM)

253.90M

-0.70%

2025

255.70M

-0.70%

2024

257.50M

-0.08%

2023

257.70M

0.62%

2022

256.10M

-0.62%

2021

257.70M

-0.82%

2020

259.84M

1.21%

2019

256.73M

0.96%

2018

254.29M

2.18%

2017

248.86M

2.16%

2016

243.59M

1.14%

2015

240.84M

2.52%

2014

234.92M

4.49%

2013

224.83M

6.08%

2012

211.95M

3.44%

2011

204.89M

2.24%

2010

200.40M

15.67%

2009

173.26M

23.27%

2008

140.56M

8.97%

2007

128.99M

13.92%

2006

113.22M

26.87%

2005

89.24M

13.58%

2004

78.57M

2.03%

2003

77.00M

1.66%

2002

75.75M

1.73%

2001

74.46M

10.02%

2000

67.68M

0.00%

회사	발행 주식 수	차이	국가
Novo Nordisk A/S NVO.US	4.45B	1,651.81%	DK
Regeneron Pharmaceuticals, Inc. REGN.US	102.90M	-59.47%	US
UCB SA UCB.BR	190.00M	-25.17%	BE
CSL Limited CSL.AX	483.58M	90.46%	AU
Argenx SE ARGX.US	61.42M	-75.81%	NL

회사

발행 주식 수

차이

국가